Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Emec who wrote (793)	7/6/1998 2:04:00 PM
From: Manny Gugliuzza	Read Replies (2) \| Respond to of 1510

i THINK THIS IS THE POINT OF WHAT CAME OUT OF THE MEETING FOR iMMUNE. It would be very useful to start some case studies with the 2x a day dose drugs at this juncture. the implications for the Immune system in general at the meeting seem to point at the individuals system regaining support on its own once the viral load is reduced without the help of Immune stimulants. but this article brings home the use of Remune to enable the body to remain off of the drugs altogether or for extended periods of time. Most or all of those with reduced viral load have returned to higher viral levels after stopping without the use of Remune. this is a huge function for this product and will nearly proves vaccine status if interval is a good length of time. but the PR is the worse ever in deliverance. we all saw that movie right? these are critical tests now in Boston but the focus is a time factor away, thus a void creating some of this downdraft in price also. here we are testing the 50 day MA AGAIN!!! Just can not stay away. ar.